What is the 13F Pro Quality Score for ALLO?

13F Pro ranks Allogene Therapeutics, Inc. (ALLO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ALLO's current score at https://13fpro.ai/research/ALLO (free sign-up required for the full ranking).

Which hedge funds own the most ALLO stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ALLO include PFIZER, BlackRock,, TPG GP A,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/ALLO as soon as new 13F filings post.

Where does 13F Pro source ALLO data?

All Allogene Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Allogene Therapeutics, Inc. files with the SEC under CIK 1737287. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ALLO in?

Allogene Therapeutics, Inc. (ALLO) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ALLO research updated on 13F Pro?

ALLO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Allogene Therapeutics, Inc.(ALLO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1737287 ALLO stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

ALLO Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Allogene Therapeutics, Inc. (ALLO), a Healthcare sector company. ALLO is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Allogene Therapeutics, Inc. reports net income of $-42.6M, free cash flow of $-12.9M. Top institutional holders of ALLO by reported 13-F value include PFIZER, BlackRock,, TPG GP A,, based on the most recent SEC filings. ALLO trades on the Nasdaq exchange and files with the SEC under CIK 1737287. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ALLO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Allogene Therapeutics, Inc. directly from SEC EDGAR. Allogene Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 3 and 23 since 2024, currently 23.4 — an improving long-term trajectory across 8 quarterly and live scoring snapshots.

Net Income

Q1 2026

$-42.6M

Free Cash Flow

Q1 2026

$-12.9M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-100.0% YoY

$0.00FY 2025

FY21 $114.1MFY23 $95.0KFY24 $22.0KFY25 $0.00

Net Income

+25.9% YoY

$-190.9MFY 2025

FY21 $-903.3MFY23 $-1.56BFY24 $-257.6MFY25 $-190.9M

Operating Income

+23.4% YoY

$-209.3MFY 2025

FY21 $-180.2MFY23 $-327.7MFY24 $-273.2MFY25 $-209.3M

EPS (Diluted)

+34.1% YoY

$-0.87FY 2025

FY21 $-1.34FY23 $-2.09FY24 $-1.32FY25 $-0.87

Total Assets

-24.2% YoY

$415.9MFY 2025

FY21 $1.05BFY23 $642.8MFY24 $548.7MFY25 $415.9M

Op. Cash Flow

+25.5% YoY

$-149.2MFY 2025

FY21 $-184.8MFY23 $-237.7MFY24 $-200.3MFY25 $-149.2M

Metric	FY 2025	FY 2024	FY 2023	FY 2021	FY 2019	FY 2018
Revenue	$0.00 -100.0%	$22.0K -76.8%	$95.0K -99.9%	$114.1M	$0.00	—
Net Income	$-190.9M +25.9%	$-257.6M +83.5%	$-1.56B -72.9%	$-903.3M -128.0%	$-396.1M -87.3%	$-211.5M
Operating Income	$-209.3M +23.4%	$-273.2M +16.6%	$-327.7M -81.9%	$-180.2M +10.8%	$-202.0M -4.8%	$-192.8M
EPS (Diluted)	$-0.87 +34.1%	$-1.32 +36.8%	$-2.09 -56.0%	$-1.34 +26.8%	$-1.83	—
Total Assets	$415.9M -24.2%	$548.7M -14.6%	$642.8M -38.8%	$1.05B +46.4%	$717.8M -7.2%	$773.9M
Operating Cash Flow	$-149.2M +25.5%	$-200.3M +15.7%	$-237.7M -28.6%	$-184.8M -34.6%	$-137.3M -207.6%	$-44.7M

AI Insight: ALLO Financial Trends

Pre-revenue biotech narrowing quarterly losses while burning cash at decelerating pace; equity base eroding as R&D spending sustains.

• Net loss improved from $66M in Q2 2024 to $39M in Q4 2025, then widened to $43M in Q1 2026.

• Operating cash burn declined from $64M in Q2 2024 to $13M in Q1 2026—78% reduction over 9 quarters.

• Shareholder equity contracted 46% from $515M to $279M between Q2 2024 and Q1 2026 amid zero revenue.

⚠ Net loss rebounded Q4 2025 to Q1 2026 (+$4M) after three consecutive quarters of improvement.

⚠ Equity base declining ~$6–7B per quarter on average; runway dependent on cash position and milestone funding.

AI Insight: ALLO Ratio Trends

Allogene remains unprofitable across all return metrics, with ROE, ROA, and ROIC all deeply negative and showing no sustained improvement trajectory.

• ROA improved from -47.0% in Q1 2025 to -37.3% in Q4 2025, but deteriorated to -43.0% in Q1 2026 TTM.

• ROIC ranged from -55.5% to -68.2% across the entire period; Q4 2025 showed relative strength at -58.0%.

• ROE worsened from -51.5% in Q2 2024 to -62.3% TTM Q1 2026, indicating deteriorating shareholder capital efficiency.

⚠ Q1 2026 TTM shows ROE, ROA, and ROIC all reversing Q4 2025 gains; reversion to higher losses after brief stabilization.

⚠ Sustained negative returns across all quarters signal ongoing cash burn without path to profitability visible in this data.

Get alerted when ALLO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Allogene Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ALLO

PFIZER INC
$49.8M22,032,040 sh
BlackRock, Inc.
$46.6M19,091,095 sh
TPG GP A, LLC
$45.7M18,716,306 sh
STATE STREET CORP
$21.1M8,660,306 sh
PRIMECAP MANAGEMENT CO/CA/
$20.4M8,379,840 sh
VANGUARD CAPITAL MANAGEMENT LLC
$16.9M6,921,350 sh
CITADEL ADVISORS LLC
$16.6M6,793,620 sh
TWO SIGMA INVESTMENTS, LP
$13.1M5,375,456 sh
GEODE CAPITAL MANAGEMENT, LLC
$10.1M4,124,178 sh
Frazier Life Sciences Management, L.P.
$9.3M3,796,668 sh

Fund	Value	Shares
PFIZER INC	$49.8M	22,032,040
BlackRock, Inc.	$46.6M	19,091,095
TPG GP A, LLC	$45.7M	18,716,306
STATE STREET CORP	$21.1M	8,660,306
PRIMECAP MANAGEMENT CO/CA/	$20.4M	8,379,840
VANGUARD CAPITAL MANAGEMENT LLC	$16.9M	6,921,350
CITADEL ADVISORS LLC	$16.6M	6,793,620
TWO SIGMA INVESTMENTS, LP	$13.1M	5,375,456
GEODE CAPITAL MANAGEMENT, LLC	$10.1M	4,124,178
Frazier Life Sciences Management, L.P.	$9.3M	3,796,668

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ALLO on your watchlist

Track score changes the day Allogene Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ALLO a good stock to buy?

13F Pro's AI-powered analysis of Allogene Therapeutics, Inc. (ALLO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ALLO are available on the ALLO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ALLO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ALLO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Allogene Therapeutics, Inc.'s investment landscape.